CN Mobile Logo

Search form


Abraxis backs SPARC as prognostic biomarker

Abraxis backs SPARC as prognostic biomarker

SPARC (secreted protein acidic and rich in cysteine) may play a role in tumor growth and angiogenesis, according to preclinical data presented at AACR 2009.

Researchers at Abraxis BioScience, the manufacturer of Abraxane (nab-paclitaxel), found that recombinant human SPARC grown in vitro fostered angiogenesis and the development of mature blood vessels. SPARC may play a greater role in the angiogenic process beyond initiating the growth of new blood vessels, they said (abstracts 1478, 2572, 3769, 4017, 5168).

Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.